Design, synthesis and biological evaluation of water-soluble phenytoin prodrugs considering the substrate recognition ability of human carboxylesterase 1.

[1]  T. Ogihara,et al.  Structure-activity relationship of atorvastatin derivatives for metabolic activation by hydrolases , 2020, Xenobiotica; the fate of foreign compounds in biological systems.

[2]  E. Ferreira,et al.  Is prodrug design an approach to increase water solubility? , 2019, International journal of pharmaceutics.

[3]  M. Hosokawa,et al.  Synthesis and evaluation of haloperidol ester prodrugs metabolically activated by human carboxylesterase , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  Yi Kang,et al.  An improved water‐soluble prodrug of propofol with high molecular utilization and rapid onset of action , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[5]  V. Sutariya,et al.  Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations , 2018, Molecules.

[6]  M. Hosokawa,et al.  Chemical synthesis of an indomethacin ester prodrug and its metabolic activation by human carboxylesterase 1. , 2018, Bioorganic & medicinal chemistry letters.

[7]  Guangbo Ge,et al.  Human carboxylesterases: a comprehensive review , 2018, Acta pharmaceutica Sinica. B.

[8]  A. Oda,et al.  Difference in substrate specificity of carboxylesterase and arylacetamide deacetylase between dogs and humans , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  G. Crespo,et al.  Phenytoin speciation with potentiometric and chronopotentiometric ion-selective membrane electrodes. , 2016, Biosensors & bioelectronics.

[10]  Y. Hamada.  Novel prodrugs with a spontaneous cleavable guanidine moiety. , 2016, Bioorganic & medicinal chemistry letters.

[11]  M. Hosokawa,et al.  Synthesis and evaluation of atorvastatin esters as prodrugs metabolically activated by human carboxylesterases. , 2016, Bioorganic & medicinal chemistry letters.

[12]  M. Chung,et al.  The Prodrug Approach: A Successful Tool for Improving Drug Solubility , 2015, Molecules.

[13]  A. Birnbaum,et al.  Intravenous and Intramuscular Formulations of Antiseizure Drugs in the Treatment of Epilepsy , 2015, CNS Drugs.

[14]  V. Herring,et al.  The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance? , 2013, Pharmacotherapy.

[15]  Masakiyo Hosokawa,et al.  Structure and Catalytic Properties of Carboxylesterase Isozymes Involved in Metabolic Activation of Prodrugs , 2008, Molecules.

[16]  Teruko Imai,et al.  Carboxylesterase in the liver and small intestine of experimental animals and human. , 2007, Life sciences.

[17]  V. Stella,et al.  Prodrug strategies to overcome poor water solubility. , 2007, Advanced drug delivery reviews.

[18]  K. Chiba,et al.  Genomic Structure and Transcriptional Regulation of the Rat, Mouse, and Human Carboxylesterase Genes , 2007, Drug metabolism reviews.

[19]  F. Akhlaghi,et al.  Anti-Influenza Prodrug Oseltamivir Is Activated by Carboxylesterase Human Carboxylesterase 1, and the Activation Is Inhibited by Antiplatelet Agent Clopidogrel , 2006, Journal of Pharmacology and Experimental Therapeutics.

[20]  K. Chiba,et al.  Dexamethasone-induced methylprednisolone hemisuccinate hydrolase: its identification as a member of the rat carboxylesterase 2 family and its unique existence in plasma. , 2005, Biochemical pharmacology.

[21]  P. Kuhn,et al.  Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. , 2003, Chemistry & biology.

[22]  J. Bosch,et al.  Synthesis of water-soluble phenytoin prodrugs. , 1999, Bioorganic & Medicinal Chemistry Letters.

[23]  Stella,et al.  Some relationships between the physical properties of various 3-acyloxymethyl prodrugs of phenytoin to structure: potential in vivo performance implications , 1998, Journal of pharmaceutical sciences.

[24]  H. Ishitsuka,et al.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.

[25]  M. Iwaki,et al.  Enhancement of oral bioavailability of phenytoin by esterification, and in vitro hydrolytic characteristics of prodrugs , 1998 .

[26]  K Hirano,et al.  Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver. , 1997, Biological & pharmaceutical bulletin.

[27]  W. Bosron,et al.  Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. , 1996, The Journal of pharmacology and experimental therapeutics.

[28]  V. Stella.  A case for prodrugs: Fosphenytoin , 1996 .

[29]  T. Satoh,et al.  Interindividual variation in carboxylesterase levels in human liver microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[30]  T. Satoh,et al.  Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. , 1994, Biological & pharmaceutical bulletin.

[31]  A. P. Lötter,et al.  Determination of the position of the ester bond in a micellar prodrug of phenytoin , 1994 .

[32]  B. Jamerson,et al.  Venous Irritation Related to Intravenous Administration of Phenytoin versus Fosphenytoin , 1994, Pharmacotherapy.

[33]  Y. Tsuda,et al.  Synthesis of some deoxy, unsaturated, and dideoxy sugars via regioselective thioacylation of glycopyranosides by the dibutyltin oxide method. , 1986 .

[34]  S. Varia,et al.  Phenytoin prodrugs III: water-soluble prodrugs for oral and/or parenteral use. , 1984, Journal of pharmaceutical sciences.

[35]  M. Blake,et al.  Determination of the pKa' value for 5,5-diphenylhydantoin. , 1968, Journal of pharmaceutical sciences.

[36]  M. Hosokawa,et al.  Investigation of the chiral recognition ability of human carboxylesterase 1 using indomethacin esters. , 2019, Chirality.

[37]  T. Fukami,et al.  The emerging role of human esterases. , 2012, Drug metabolism and pharmacokinetics.